Bevacizumab-induced laryngeal necrosis. [electronic resource]
Producer: 20120411Description: 276-278 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- drug therapy
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Carboplatin -- administration & dosage
- Cisplatin -- administration & dosage
- Clinical Trials, Phase I as Topic
- Deoxycytidine -- administration & dosage
- Female
- Glutamates -- administration & dosage
- Guanine -- administration & dosage
- Humans
- Laryngeal Diseases -- chemically induced
- Lung Neoplasms -- drug therapy
- Middle Aged
- Necrosis -- chemically induced
- Neoplasm Recurrence, Local -- drug therapy
- Paclitaxel -- administration & dosage
- Pemetrexed
- Tubulin Modulators -- administration & dosage
- Gemcitabine
No physical items for this record
Publication Type: Case Reports; Letter
There are no comments on this title.
Log in to your account to post a comment.